Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanifibranor phase 3 trial in adults with non-cirrhotic NASH and F2/F3 fibrosis
NL-OMON59366Phase 3Active, not recruiting
- Sponsor
- Inventiva
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lanifibranor in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Inventiva. Started Feb 2022; status: active, not recruiting.
02
Drugs
lanifibranor
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NL-OMON59366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59366.